Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000132534 | SCV000187631 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-06-25 | criteria provided, single submitter | clinical testing | The c.2498_2499delAA pathogenic mutation, located in coding exon 15 of the RAD50 gene, results from a deletion of two nucleotides at nucleotide positions 2498 to 2499, causing a translational frameshift with a predicted alternate stop codon (p.Q833Rfs*11). This pathogenic mutation was observed in a study of high-risk breast cancer patients who underwent multi-gene panel testing (Lin PH et al. Oncotarget 2016 Feb;7(7):8310-20). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Invitae | RCV000132534 | SCV000548004 | pathogenic | Hereditary cancer-predisposing syndrome | 2023-12-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln833Argfs*11) in the RAD50 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD50 are known to be pathogenic (PMID: 19409520). This variant is present in population databases (rs587782895, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 26824983). ClinVar contains an entry for this variant (Variation ID: 143015). For these reasons, this variant has been classified as Pathogenic. |
Counsyl | RCV000662958 | SCV000785928 | pathogenic | Nijmegen breakage syndrome-like disorder | 2018-01-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000662958 | SCV004207421 | pathogenic | Nijmegen breakage syndrome-like disorder | 2022-12-27 | criteria provided, single submitter | clinical testing |